The {pharmaceutical sector is increasingly exploring novel treatment approaches for obesity , and the arrival of semaglutide 10mg injectables represents a development . Clinicians are beginning to evaluate the possible benefits and drawbacks associated with this increased strength product, particularly in relation to existing less potent semaglutid